Patient-Derived Xenograft Models of Breast Cancer

Patient-derived xenograft (PDX) models provide a true representation of human heterogeneity and can be used to test the efficacy of novel compounds against drug resistance.

Benefits of Our Breast Cancer PDX Models

Our breast cancer PDX models offer the most translational preclinical models for efficacy screening in cancer drug development. Derived directly from patient tumors and never adapted to grow in vitro, patient-derived xenografts reflect the heterogeneity and diversity of the human patient population. PDX models give you an accurate, predictive model of how your compound will perform before entering clinical trials. Crown Bioscience’s breast cancer PDX model collection, known as HuPrime^®, is well characterized for pathology, growth characteristics, and are also genetically and genomically annotated for gene expression, gene copy number, mutations, and fusions.